ARWR
Price
$31.66
Change
-$1.17 (-3.56%)
Updated
Sep 25, 04:59 PM (EDT)
Capitalization
4.38B
67 days until earnings call
FULC
Price
$8.52
Change
+$0.27 (+3.27%)
Updated
Sep 25, 04:59 PM (EDT)
Capitalization
446.26M
48 days until earnings call
Interact to see
Advertisement

ARWR vs FULC

Header iconARWR vs FULC Comparison
Open Charts ARWR vs FULCBanner chart's image
Arrowhead Pharmaceuticals
Price$31.66
Change-$1.17 (-3.56%)
Volume$51.79K
Capitalization4.38B
Fulcrum Therapeutics
Price$8.52
Change+$0.27 (+3.27%)
Volume$4.73K
Capitalization446.26M
ARWR vs FULC Comparison Chart in %
Loading...
ARWR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
FULC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ARWR vs. FULC commentary
Sep 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARWR is a Hold and FULC is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 26, 2025
Stock price -- (ARWR: $32.83 vs. FULC: $8.25)
Brand notoriety: ARWR: Notable vs. FULC: Not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARWR: 86% vs. FULC: 76%
Market capitalization -- ARWR: $4.38B vs. FULC: $446.26M
ARWR [@Biotechnology] is valued at $4.38B. FULC’s [@Biotechnology] market capitalization is $446.26M. The market cap for tickers in the [@Biotechnology] industry ranges from $97.91B to $0. The average market capitalization across the [@Biotechnology] industry is $1.91B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARWR’s FA Score shows that 1 FA rating(s) are green whileFULC’s FA Score has 1 green FA rating(s).

  • ARWR’s FA Score: 1 green, 4 red.
  • FULC’s FA Score: 1 green, 4 red.
According to our system of comparison, both ARWR and FULC are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARWR’s TA Score shows that 3 TA indicator(s) are bullish while FULC’s TA Score has 6 bullish TA indicator(s).

  • ARWR’s TA Score: 3 bullish, 3 bearish.
  • FULC’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, FULC is a better buy in the short-term than ARWR.

Price Growth

ARWR (@Biotechnology) experienced а +12.70% price change this week, while FULC (@Biotechnology) price change was +12.70% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.96%. For the same industry, the average monthly price growth was +8.68%, and the average quarterly price growth was +48.56%.

Reported Earning Dates

ARWR is expected to report earnings on Dec 01, 2025.

FULC is expected to report earnings on Nov 12, 2025.

Industries' Descriptions

@Biotechnology (+0.96% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ARWR($4.38B) has a higher market cap than FULC($446M). FULC (75.532) and ARWR (74.628) have similar YTD gains . ARWR has higher annual earnings (EBITDA): -52.51M vs. FULC (-81.28M). ARWR has more cash in the bank: 900M vs. FULC (214M). FULC has less debt than ARWR: FULC (7.57M) vs ARWR (353M). ARWR has higher revenues than FULC: ARWR (573M) vs FULC (0).
ARWRFULCARWR / FULC
Capitalization4.38B446M981%
EBITDA-52.51M-81.28M65%
Gain YTD74.62875.53299%
P/E RatioN/AN/A-
Revenue573M0-
Total Cash900M214M421%
Total Debt353M7.57M4,663%
FUNDAMENTALS RATINGS
ARWR vs FULC: Fundamental Ratings
ARWR
FULC
OUTLOOK RATING
1..100
2412
VALUATION
overvalued / fair valued / undervalued
1..100
94
Overvalued
24
Undervalued
PROFIT vs RISK RATING
1..100
10096
SMR RATING
1..100
9797
PRICE GROWTH RATING
1..100
3538
P/E GROWTH RATING
1..100
2100
SEASONALITY SCORE
1..100
n/a24

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

FULC's Valuation (24) in the null industry is significantly better than the same rating for ARWR (94) in the Biotechnology industry. This means that FULC’s stock grew significantly faster than ARWR’s over the last 12 months.

FULC's Profit vs Risk Rating (96) in the null industry is in the same range as ARWR (100) in the Biotechnology industry. This means that FULC’s stock grew similarly to ARWR’s over the last 12 months.

FULC's SMR Rating (97) in the null industry is in the same range as ARWR (97) in the Biotechnology industry. This means that FULC’s stock grew similarly to ARWR’s over the last 12 months.

ARWR's Price Growth Rating (35) in the Biotechnology industry is in the same range as FULC (38) in the null industry. This means that ARWR’s stock grew similarly to FULC’s over the last 12 months.

ARWR's P/E Growth Rating (2) in the Biotechnology industry is significantly better than the same rating for FULC (100) in the null industry. This means that ARWR’s stock grew significantly faster than FULC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARWRFULC
RSI
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 2 days ago
74%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
83%
Momentum
ODDS (%)
N/A
Bullish Trend 2 days ago
89%
MACD
ODDS (%)
N/A
Bullish Trend 2 days ago
88%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
87%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 2 days ago
87%
Advances
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 8 days ago
87%
Declines
ODDS (%)
N/A
Bearish Trend 16 days ago
85%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
78%
Aroon
ODDS (%)
Bullish Trend 2 days ago
73%
Bullish Trend 2 days ago
82%
View a ticker or compare two or three
Interact to see
Advertisement
ARWR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
FULC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
NGISX18.52N/A
N/A
Nationwide BNY Mellon Dyn US Core I.S
TGVRX31.83N/A
N/A
Thornburg International Equity R3
LVOCX14.68N/A
N/A
Lord Abbett Value Opportunities C
BRSVX39.24N/A
N/A
Bridgeway Small-Cap Value
MSSCX9.48N/A
N/A
AMG Frontier Small Cap Growth I

FULC and

Correlation & Price change

A.I.dvisor indicates that over the last year, FULC has been loosely correlated with ADPT. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if FULC jumps, then ADPT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To FULC
1D Price
Change %
FULC100%
+12.24%
ADPT - FULC
48%
Loosely correlated
-7.97%
SLS - FULC
48%
Loosely correlated
-4.12%
ARWR - FULC
46%
Loosely correlated
+1.02%
BEAM - FULC
45%
Loosely correlated
-0.59%
TRDA - FULC
45%
Loosely correlated
+1.18%
More